Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 16, 2018

PAVmed finalises EsoCheck technology licensing deal

Medical device company PAVmed has finalised its definitive licensing agreement with Case Western Reserve University for the development and commercialisation of EsoCheck technology to diagnose Barrett’s Esophagus.

Medical device company PAVmed has finalised its definitive licensing agreement with Case Western Reserve University for the development and commercialisation of EsoCheck technology to diagnose Barrett’s Esophagus.

Originally proposed in April this year, the deal involves the grant of an exclusive worldwide licence by the university to a newly-formed PAVmed subsidiary, Lucid Diagnostics.

The licensed portfolio consists of additional biomarkers to detect changes in the oesophagus for screening, diagnosis, disease staging, monitoring and prognosis.

“EsoCheck is comprised of a non-invasive cell sampling device and a DNA biomarker test that demonstrates high accuracy in detecting Barrett’s Esophagus, an oesophageal condition which could lead to cancer.”

In turn, the university received a minority equity stake in Lucid Diagnostics, while PAVmed retained around 82% of the equity interest.

The deal is subject to select regulatory and commercialisation milestones, and the university is eligible for royalties based on revenue and a certain proportion of any additional proceeds.

EsoCheck is comprised of a non-invasive cell sampling device and a DNA biomarker test that demonstrates high accuracy in detecting Barrett’s Esophagus, an oesophageal condition which could lead to cancer.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

The office-based alternative to endoscopy can be performed in five minutes and involves the administration of a silicone-covered capsule that carries a small inflatable balloon linked to a thin catheter.

During withdrawal, the catheter swabs the target site for a sample of cells and protects it against contamination while the device is retracted.

The obtained sample is tested for a panel of methylated DNA biomarkers that have been validated to be accurate in detecting Barrett’s Esophagus.

EsoCheck is being evaluated in a multi-centre National Institutes of Health (NIH) study in patients at Case Western Reserve University Hospital and other academic medical centres across the US.

PAVmed chairman and CEO Lishan Aklog said: “The EsoCheck device is already being manufactured for human use in clinical trials and the EsoCheck DNA biomarker test is already being performed at a reference laboratory, which expects to receive CLIA certification later this year.

“As such, we will be able to aggressively pursue EsoCheck commercialisation by seeking US Food and Drug Administration (FDA) 510(k) clearance of the cell sampling device and a Laboratory Developed Test designation of the DNA biomarker test.”

The company intends to commercially launch EsoCheck in the US in the first quarter of next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU